New cellular model for rare and deadly melanomas enables study of immunotherapy resistance

Article excerpt

A research team at the University of Turku in Finland has developed a reliable laboratory model to study BAP1-deficient melanomas, which are a rare type of melanoma that evade the immune system once they have metastasized and are universally resistant to current state-of-the-art immunotherapies. The tool could change how therapies are developed for aggressive melanomas that currently have almost no effective treatment options.